【Yuuu】評論

lupus anticoagulants (LA) 是一個非常奇特的疾病，雖然說他有抗磷指抗體，但是他會造成血栓!! 這個非常重要，請大家要牢記LA的臨床症狀有:動/靜脈栓塞、反覆性流產、thrombocytopenia、網狀青斑(livedo reticularis)

【7you】評論

lupus anticoagulants (LAC) 是一群抗磷質抗體 造成 antiphospholipid sydrome在體內臨床  (結合特定磷脂質誘發血小板凝集發炎反應) 會促進 血栓 發炎 反覆不明流產(婦科不孕症找不出原因會驗) 在體外LAB  因為檢驗方法原理會縮短凝血時間LAC is measured by applying two phospholipid-dependent coagulation tests, the diluted Russell’s viper venom time (dRVVT) and LAC-sensitive activated partial thromboplastin time (aPTT). In dRVVT, factor X is directly activated by Russell’s viper venom (RVV), consequently activating prothrombin to thrombin in a phospholipid-, calcium-, and activated factor V-dependent way. Thrombin will further convert fibrinogen into fibrin, which can be detected mechanically or optically. In aPTT, factor XII is activated by a contact activator (silica) which initiates a sequence of activation of factor XI, IX, X, prothrombin, and conversion of fibrinogen to fibrin. Both activation of factors IX and X depends on phospholipids. Antiphospholipid antibodies present in the patient plasma sample will compete with coagulation factors for phospholipids through binding with phospholipid-bound cofactors such as β2-glycoprotein I, resulting in a prolonged clotting time. Positive screening assays are followed by mixing and confirmation tests. In aCL assays, a solid phase is coated with cardiolipin which forms a complex with β2GPI and aβ2GPI assays are coated with β2GPI. Patient aCL or aβ2GPI can bind to the antigen on the solid phase. Subsequent binding of reagent anti-human IgG/IgM antibody labeled with conjugate leads to conversion of a substrate into a measurable product. 診斷 : at least one clinical criterion +a least one laboratory criterion over at least 12 weeks